Innate Immune Stimulation in Cancer Therapy

Peter Düwell; Simon Heidegger; Sebastian Kobold

doi:10.1016/j.hoc.2018.12.002

Innate Immune Stimulation in Cancer Therapy

Hematol Oncol Clin North Am. 2019 Apr;33(2):215-231. doi: 10.1016/j.hoc.2018.12.002. Epub 2019 Jan 9.

Authors

Peter Düwell¹, Simon Heidegger², Sebastian Kobold³

Affiliations

¹ Institute of Innate Immunity, University of Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany.
² Medizinische Klinik und Poliklinik 3, Klinikum rechts der Isar, Technische Universität München, Ismaningerstrasse 22, Munich 81675, Germany.
³ Division of Clinical Pharmacology, Center of Integrated Protein Science Munich (CIPS-M), Klinikum der Universität München, Lindwurmstrasse 2a, Munich 80337, Germany. Electronic address: sebastian.kobold@med.uni-muenchen.de.

PMID: 30832996
DOI: 10.1016/j.hoc.2018.12.002

Abstract

The innate immune system has evolved as a first line of defense against invading pathogens and acts via classes of germline-encoded receptor systems to respond with proinflammatory cytokines. Innate immune cells, predominantly cells of the myeloid compartment, are capable of providing a potent basis for boosting adaptive immunity in malignant diseases. The authors review their current understanding of the molecular mechanisms whereby innate pattern recognition receptors participate in immunosurveillance of cancer cells. They discuss how innate effector mechanisms are currently being targeted pharmacologically and how improved understanding of the biology of these pathways is leading to novel immunotherapies of cancer.

Keywords: Antibodies; Cancer; Innate immunity; NLR; Oncoimmunology; RLH; STING; TLR.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Adaptive Immunity*
Animals
Humans
Immunity, Innate*
Immunotherapy*
Neoplasms / immunology*
Neoplasms / therapy*

Grants and funding

756017/ERC_/European Research Council/International